Quantum technology is moving into a new capital phase. The market remains early, technical approaches continue to compete, and commercial adoption varies substantially by use case. Yet the funding environment has already changed: larger private rounds, strategic transactions and consolidation are increasing the financial stakes of technical progress.
That creates a distinctive underwriting problem. Investors are being asked to price companies before the end-state architecture, customer economics and timing of broad commercial utility are fully known. A disciplined framework therefore needs to connect scientific progress to financing runway, strategic value and evidence of customer demand.
01 / Capital is concentrating
McKinsey’s 2026 Quantum Technology Monitor reported US$12.6 billion of investment in quantum-technology start-ups during 2025, 6.3 times the prior year, with roughly 90% directed to quantum-computing companies. The report also found that around 60% of 2025 investment was concentrated in the ten largest deals. Concentration can accelerate technical road maps, but it raises the importance of understanding which companies can convert capital into defensible technical and commercial milestones.
Large rounds can reduce near-term financing risk, but they can also increase the milestone burden. A company that raises significant capital at a higher valuation may need to demonstrate a much larger technical or commercial step before the next round or exit can be justified.
02 / Quantum cannot be underwritten like conventional software
A software company can often be evaluated using product adoption, retention, gross margin and sales efficiency. Quantum hardware requires a different lens. Engineering progress, error rates, system scale, control systems, fabrication dependencies, cryogenics, specialized talent and access to customers can all be material to the business model.
That means valuation cannot be separated from the technical road map. A milestone that meaningfully reduces the path to a useful system may change financing needs and strategic value. A milestone that is impressive scientifically but does not improve commercial viability may have less investment significance.
03 / Four layers of the quantum economy
Hardware platforms
Capital-intensive systems where architecture, manufacturing, scaling, control and performance milestones dominate the thesis. Hardware underwriting should examine which resources become more difficult as systems scale and whether the approach has a credible manufacturing or supply-chain path.
Enabling technologies
Control electronics, photonics, cryogenics, components, packaging and specialized infrastructure may benefit from multi-platform demand. These businesses can sometimes offer a different risk profile because they sell into more than one architecture or into adjacent advanced-computing markets.
Software and access
Cloud access, development tools, orchestration and application software may resemble enterprise technology more closely, but commercial value still depends on hardware maturity and the ability to solve customer problems better than classical alternatives.
Sensing and communications
Quantum sensing and networking can have different commercialization timelines from general-purpose quantum computing. They should be analyzed on their own customer, deployment, regulatory and infrastructure economics rather than treated as one technology category.
04 / Commercialization evidence should be staged
Quantum commercialization is not binary. Investors can track a progression from research collaboration to paid pilot, repeat engagement, production deployment and recurring revenue. Each stage provides different evidence about customer value and implementation friction.
Partnership announcements can be strategically useful but should not automatically be treated as revenue validation. A stronger diligence process asks whether customers are paying, whether use cases are repeated, how much technical support is required, and whether the economic benefit is expected to exceed the cost and complexity of deployment.
05 / Financing runway is part of technical risk
For a capital-intensive quantum company, the next financing round can be as consequential as the next engineering milestone. Underwriting should map cash runway against the technical plan and identify what must be achieved before additional capital is required.
If a company requires new financing before a value-inflecting milestone, existing investors carry dilution and funding risk even if the long-term science remains promising. Conversely, a well-funded company with clear milestone sequencing may have more strategic flexibility to recruit scarce talent, secure equipment and withstand technical delays.
06 / Strategic transactions matter before full maturity
Consolidation can be an important signal in an emerging technology market. Acquisitions can provide talent, intellectual property, manufacturing capability, customer access or complementary technical approaches. Strategic buyers may value those capabilities before standalone financial metrics would support a conventional buyout case.
Transaction activity should not be treated as proof that the entire category has reached commercial maturity. The value of each deal depends on what capability is being acquired, how it changes the buyer’s road map, and whether integration creates a credible advantage rather than simply adding another technical approach.
07 / The underwriting questions
New York AI™ frames quantum research around eight questions:
- Milestone — What technical milestone must be reached next, and why does it matter?
- Capital — How much capital is required to reach that milestone with adequate contingency?
- Runway — Does the company need to refinance before the milestone can be demonstrated?
- Dependencies — Which fabrication, supply-chain, infrastructure or ecosystem dependencies sit outside management control?
- Customer evidence — What paid, repeated or production-level evidence exists today?
- Differentiation — Is the advantage measurable and durable across competing technical approaches?
- Strategic value — Could the company have acquisition or partnership value before full-scale commercialization?
- Downside — What assets, intellectual property, talent or customer relationships retain value if the primary technical thesis takes longer?
08 / What changes the investment case
The highest-value information in an emerging technology market is often evidence that changes the financing path. A technical result that reduces capital requirements, a customer contract that improves revenue visibility, a manufacturing partnership that removes a scaling constraint, or an acquisition that shortens the road map can all alter the risk profile.
Investors should separate category momentum from company-level evidence. Rising sector funding can improve access to talent and capital, but it can also increase competition and valuation. The relevant question is what makes one company’s technical and financing path more credible than the alternatives.
09 / Research conclusion
The quantum economy is becoming investable before it becomes predictable. That creates opportunity and risk. A disciplined approach must connect technical milestones to capital requirements, financing runway and commercial evidence. Category growth is useful context; company-level underwriting remains the central task.
For institutional investors, the core discipline is to avoid translating scientific excitement directly into financial certainty. Technical progress matters most when it changes the probability, timing or economics of commercialization.
10 / Selected references
- McKinsey & Company — Quantum Technology Monitor 2026
- Boston Consulting Group — Meet the New Generation of AI Disruptors (June 2026)
New York AI™ research is provided for general informational and research purposes. Sources are selected for relevance and are subject to revision as markets, technology and underlying data change. Readers should perform their own diligence and consult appropriate professional advisers before making investment or transaction decisions.